ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q2 twenty twenty six Earnings Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Thursday, 08/13/2026. I would now like to turn the conference over to Nicole Reilly, Head of Investor Relations and Corporate Communications. Please go ahead. Thank you, operator. Today, we issued a press release announcing our second quarter twenty twenty six financial results and business update. This release and the slides we will use in today's presentation are available on the Investors section of the ADC Therapeutics website. I'm joined on today's call by our Chief Executive Officer, Amit Malik, who will discuss our operational performance and recent business highlights, followed by our Chief Medical Officer, Mohammad Zaki, who will provide clinical and regulatory updates and lastly, our Chief Financial Officer, Pepe Carmona, who will review our second quarter twenty twenty six financial results. We will then open the call to questions. Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward looking statements within the meaning of the Safe Harbor provisions of The U. S. Private Securities Litigation Reform Act of 1995. These forward looking statements are subject to certain known and unknown risks and uncertainties, and actual results, performance and achievements could differ materially. They are identified and described in the accompanying slide presentation and in the company's filings with the SEC, including Form 10 ks, 10 Q, and eight ks. ADC Therapeutics is providing this information as of today's date and does...